TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02987920
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal analgesic regimen to Group A and Group B
Study: NCT02987920
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal analgesic regimen to Group A and Group B
Study: NCT04461119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules for 4 weeks of treatment
Study: NCT01876550
Drug: Mupirocin Calcium Cream, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Study: NCT01876550
Drug: Bactroban® Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
Study: NCT00427713
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03606876
Drug: BAT1806 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
Study: NCT03433755
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
Study: NCT01850095
Drug: dorspirenone/ethynil estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04223778
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
Study: NCT04612517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; corresponding volume
Study: NCT01224028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04082728
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
Study: NCT05173246
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 240mg, ivdrip, d1, Q3w
Study: NCT01369017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of NS
Study: NCT00003034
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04016792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily
Study: NCT04016792
Drug: 200 mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SPN-812 will be administered once daily and compared to Placebo
Study: NCT01651143
Drug: SAR100842
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT01651143
Drug: Placebo (for SAR100842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT02894138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00618930
Drug: Moviprep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of Moviprep®
Study: NCT04337684
Drug: Long Term Follow-Up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up.
Study: NCT01962181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05055895
Drug: Anticholinergic burden
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1.
Study: NCT00219583
Drug: UK-390,957
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02961166
Drug: IgM enriched Immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for 3 days
Study: NCT02707250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
Study: NCT00269542
Drug: Zinc and iron folic acid - Intervention
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
Study: NCT00269542
Drug: Iron Folic Acid alone - Placebo
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
Study: NCT04060342
Drug: GB1275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04498741
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive rosuvastatin once daily on Day 1 and Day 13
Study: NCT04214717
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will only receive Chemotherapy.
Study: NCT04080297
Drug: oral capsule of Q-122
Normalized name: ubidecarenone / vitamin E Oral Capsule [Q-Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01261741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive matching placebo tablets once daily
Study: NCT00292188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00795808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet tds for 6 months
Study: NCT04449757
Drug: Bicarbonated Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Study: NCT00812422
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one dose of Ibuprofen 5 or 10 mg/kg
Study: NCT01034787
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
Study: NCT01936519
Drug: Calcineurin Inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
Study: NCT01764295
Drug: DWJ1276
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01764295
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01764295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02744391
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02276898
Drug: Hypertonic Saline 7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI Hyper-Sal™ Sodium Chloride Solution - 7%
Study: NCT04616924
Drug: RHB-204
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHB-204
Study: NCT04616924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to RHB-204
Study: NCT02276898
Drug: Isotonic Saline 0.9% (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00046449
Drug: Investigational Seasonal Affective Disorder (SAD) Drug
Normalized name: INVESTIGATIONAL DRUGS FOR MANIA AND BIPOLAR DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01455337
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg qd
Study: NCT01572545
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
Study: NCT00040937
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
Study: NCT04292886
Drug: Vitamin C and femoston
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and femoston
Study: NCT00558909
Drug: placebo for BI 44847
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02960061
Drug: Hyperthermic intraperitoneal perfusion chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
Study: NCT02960061
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
Study: NCT00771381
Drug: 18F-FAZA PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
Study: NCT00771381
Drug: FluGlucoScan Injection (18F-FDB) PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
Study: NCT04561687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and nasal budesonide
Study: NCT00941057
Drug: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
Study: NCT00941057
Drug: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
Study: NCT01566357
Drug: Tooth Mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566357
Drug: MI Paste Plus
Normalized name: Calcium Phosphate/Sodium Fluoride 0.2% Oromucosal Cream [GC MI PASTE PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566357
Drug: Elmex Erosion Protection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00578071
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
Study: NCT01791153
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Study: NCT01791153
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Study: NCT02918747
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
Study: NCT02918747
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
Study: NCT02537873
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose in gelatin capsule
Study: NCT03408756
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive methotrexate through oral or subcutaneous route of administration
Study: NCT03626506
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
Study: NCT03626506
Drug: Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
Study: NCT00025636
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025636
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03923530
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 50 mg daily
Study: NCT00530686
Drug: Islet cell transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
Study: NCT02560441
Drug: IPGDP regimen chemotherapy
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02989168
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBT440: Capsules which contain GBT440 drug substance in Swedish orange
Study: NCT03585465
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Study: NCT03585465
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Study: NCT01029821
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated Ankle Fracture Single planned operation
Study: NCT01941940
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT03436914
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
Study: NCT01301508
Drug: AN2728 ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 ointment, 2%, applied twice daily for 6 weeks
Study: NCT01301508
Drug: AN2728 ointment vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 ointment vehicle applied twice daily for 6 weeks
Study: NCT03731221
Drug: Bupi HCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
Study: NCT01124708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
Study: NCT04451603
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
Study: NCT01086475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
Study: NCT03372811
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03331562
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution for injection
Study: NCT01832675
Drug: Xylocain, cutaneous spray, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
Study: NCT01679587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of matching placebo will be given in each treatment arm
Study: NCT02246439
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04551911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg calcifediol Extended-Release (ER) Capsule
Study: NCT03734211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Study: NCT00380692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02556788
Drug: CD5789 (trifarotene) 50µg/g Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
Study: NCT02556788
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied once daily during 12 weeks.
Study: NCT01706627
Drug: 10 mg Melatonin
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active Comparator: Drug: Melatonin 10 mg
Study: NCT01706627
Drug: 20 mg Melatonin
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active Comparator: Drug: Melatonin 20 mg
Study: NCT01706627
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (identical formulation and delivery, without active ingredient)
Study: NCT01381640
Drug: Marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed formulation
Study: NCT01769339
Drug: Miconazole plus Hydrocortisone
Normalized name: hydrocortisone / miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
Study: NCT01381640
Drug: Experimental paracetamol formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulation
Study: NCT00704730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Study: NCT05000086
Drug: 99Tc methylene diphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22mg qd，Once a day for 7 consecutive days
Study: NCT00666848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
Study: NCT01332578
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product
Study: NCT05154812
Drug: Yang Yin Fu Zheng Jie Du therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study: NCT05154812
Drug: Routine medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical care
Study: NCT01029158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02327117
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02637375
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02637375
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02858492
Drug: GSK2982772 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Study: NCT02858492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Study: NCT01509742
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement